DoMore Diagnostics and Gustave Roussy Announce Clinical Research Collaboration
OSLO – October 8, 2024 – DoMore Diagnostics, a leader in AI and deep learning precision medicine for cancer, and Gustave Roussy (Paris, France), Europe’s #1 and the world’s #4 ranked cancer hospital, have entered into a collaboration agreement to clinically validate Histotype Px® Colorectal in French stage II and stage III colorectal cancer patients.
The study will utilize H&E slides from resected tumor specimens and matching biopsies together with clinical outcome data. The objective of the study is to test and document the performance of Histotype Px® Colorectal in this patient population and support adoption and clinical use of Histotype Px® Colorectal as a predictive digital biomarker to guide treatment decisions in colorectal cancer patients.
Dr. Mohamed-Amine Bani at the Medical Biology and Pathology Department, Gustave Roussy Cancer Campus, an expert in the field of colorectal cancer, will lead the multidisciplinary team of oncologists and researchers from Gustave Roussy: “Gustave Roussy aims to be at the forefront of personalized cancer treatment innovation. There is currently a lack of reliable biomarkers to guide treatment decisions in colorectal cancer. DoMore Diagnostic’s digital biomarker Histotype Px Colorectal addresses a large unmet medical need and we are very excited about the potential utility of this tool to improve the treatment we can offer this patient population.”
"We are very proud to be partnering with world-leading physicians and researchers at Gustave Roussy to validate Histotype Px Colorectal in a French patient population as a predictive test to guide treatment decisions, said Dr. Torbjørn Furuseth, CEO and Co-Founder of DoMore Diagnostics. "Gustave Roussy is a European powerhouse in developing and implementing cutting-edge innovations to improve the treatment and lives of cancer patients, which is perfectly aligned with our mission at DoMore Diagnostics. The study is another major milestone towards validating the potential of and need for Histotype Px as a predictive marker to guide treatment decisions and support inclusion in clinical guidelines. This collaboration also aims to investigate the performance on biopsies and across scanners, which will further broaden the application of Histotype Px Colorectal.”
About Gustave Roussy
Ranked as the leading French and European Cancer Centre and fourth in the world, Gustave Roussy is a centre with comprehensive expertise and is devoted entirely to patients suffering with cancer. The Institute is a founding member of the Paris Saclay Cancer Cluster. It is a source of diagnostic and therapeutic advances. It caters for almost 50,000 patients per year and its approach is one that integrates research, patient care and teaching. It is specialized in the treatment of rare cancers and complex tumors and it treats all cancers in patients of any age. Its care is personalized and combines the most advanced medical methods with an appreciation of the patient’s human requirements. In addition to the quality of treatment offered, the physical, psychological and social aspects of the patient’s life are respected. 4,100 professionals work on its two campuses: Villejuif and Chevilly-Larue. Gustave Roussy brings together the skills, which are essential for the highest quality research in oncology: 40% of patients treated are included in clinical studies.
For further information: www.gustaveroussy.fr/en, X, Facebook, LinkedIn, Instagram
About DoMore Diagnostics
DoMore Diagnostics uses artificial intelligence to make personalized treatment decisions simple and accessible for all cancer patients. Its unique digital biomarkers predict patient outcomes from routine tumor tissue slides and can be seamlessly integrated into pathologists’ existing workflow. The lead product Histotype Px® Colorectal is a CE-IVDD marked outcome prediction marker for stage II and III colorectal adenocarcinoma that informs the decision of whether to provide adjuvant chemotherapy following surgical resection of the tumor.
About Colorectal Cancer and Histotype Px® Colorectal
Colorectal cancer is the third most common and second most deadly cancer but has seen little innovation in diagnostics and treatment in the last decades. Adjuvant chemotherapy (ACT) may be provided after primary surgery to prevent the disease from recurring, however overtreatment is prevalent with up to 85% of patients with stage II and stage III not benefiting from ACT and only suffering side effects.
Histotype Px® is an advanced deep learning algorithm that analyzes digital histology slides, identifying patients who may or may not benefit from adjuvant chemotherapy. Data previously published in The Lancet and Lancet Oncology showed the test can accurately predict survival outcomes in colorectal cancer patients. Histotype Px® Colorectal was developed to provide clinicians with valuable information to guide personalized treatment decisions and improve patient outcomes.
For more information about the Histotype Px Colorectal biomarker, please visit:
The Lancet publication.
The Lancet Oncology publication.
Contact:
Torbjørn Furuseth, MD
torbjorn.furuseth@domorediagnostics.com